ProPhase Labs (NASDAQ:PRPH) Stock Crosses Below 200 Day Moving Average – Here’s Why

ProPhase Labs, Inc. (NASDAQ:PRPH)’s stock price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.14 and traded as low as $0.13. ProPhase Labs shares last traded at $0.1364, with a volume of 82,635 shares traded.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised ProPhase Labs to a “hold” rating in a research note on Saturday, December 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, ProPhase Labs has an average rating of “Sell”.

ProPhase Labs Stock Performance

The company has a debt-to-equity ratio of 0.14, a current ratio of 0.14 and a quick ratio of 0.14. The stock’s 50-day moving average price is $0.18 and its 200 day moving average price is $2.10. The firm has a market cap of $899,686.80, a P/E ratio of -0.04 and a beta of -0.52.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. XTX Topco Ltd bought a new stake in ProPhase Labs during the 2nd quarter worth $40,000. Apollon Wealth Management LLC acquired a new position in shares of ProPhase Labs in the third quarter worth approximately $84,000. Accretive Wealth Partners LLC bought a new stake in ProPhase Labs in the third quarter valued at approximately $114,000. Susquehanna International Group LLP boosted its holdings in ProPhase Labs by 290.1% in the third quarter. Susquehanna International Group LLP now owns 397,914 shares of the company’s stock valued at $182,000 after acquiring an additional 295,899 shares during the last quarter. Finally, Sykon Capital LLC acquired a new stake in ProPhase Labs during the 2nd quarter valued at approximately $252,000. 9.45% of the stock is currently owned by institutional investors and hedge funds.

ProPhase Labs Company Profile

ProPhase Labs, Inc is a U.S.-based specialty health sciences company that develops, manufactures and markets a range of diagnostic and therapeutic products. The company’s operations span infectious disease testing services, over-the-counter remedies and contract manufacturing for pharmaceutical and consumer health clients. ProPhase Labs leverages both in-house production facilities and distribution networks to bring targeted solutions to market.

In its diagnostics division, ProPhase Labs offers laboratory-based testing for respiratory and infectious diseases, employing molecular and immunoassay technologies.